Ophthalmology

Avacincaptad pegol shows potential in geographic atrophy secondary to AMD

20 hours ago

In eyes with age-related macular degeneration (AMD), intravitreal administration of the complement C5 inhibitor avacincaptad pegol appears to reduce the growth of geographic atrophy, according to the results of a phase II/III trial.

Dexamethasone implants stall but do not reverse VA loss in macular oedema after RVO

Yesterday

Dexamethasone intravitreal implants (DII) can help maintain visual acuity (VA) in patients with macular oedema (ME) due to retinal vein occlusion (RVO) but cannot seem to reverse VA loss, a recent study has found.

Novel prediction model detects progression to advanced AMD

5 days ago

A comprehensive prediction model that applies a machine learning algorithm allowing selection of the most predictive risk factors automatically achieves high discrimination abilities in calculating progression to advanced age-related macular degeneration (AMD), as shown in two cohort studies.

SARS-CoV-2 transmissible in tears of patients with moderate to severe COVID-19

Stephen Padilla, 16 Apr 2021

COVID-19 may be transmitted through tears, as shown in some patients with laboratory-proven moderate to severe disease, according to a study. Conjunctival swab is a satisfactory method of collecting tears for assessing the presence of SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR).

Novel drug delivery system reduces treatment burden in neovascular AMD

Dr. David Eichenbaum, Dr. Dilsher Dhoot, Prof. Peter Campochiaro, Dr. Timothy Y Y Lai, 04 Sep 2020

Intravitreal injection of antiangiogenic agents is the standard of care for neovascular age-related macular degeneration (nAMD), however, frequent injections represent a considerable treatment burden for patients. Results of the Ladder and Archway studies, presented at the 38th Annual Meeting of the American Society of Retina Specialists (ASRS 2020), showed that administration of ranibizumab through a port delivery system (PDS) considerably reduced treatment burden, while maintaining comparable efficacy and safety vs intravitreal injections. In an interview with MIMS Doctor, Dr Timothy Lai of Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, discusses how PDS may transform the management of nAMD.

No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia

Roshini Claire Anthony, 28 Jun 2020

Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.